文献速递妇科肿瘤

体细胞BRCA1/2功能恢复作为对聚腺苷二磷酸核糖聚合酶抑制剂卓越应答后的耐药机制

Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.
PubMed 文献 · J Clin Oncol · 2017-02-21

该研究对3例无胚系BRCA1/2突变但接受奥拉帕利单药治疗超过5年且疗效卓越的高级别浆液性卵巢癌患者的诊断和复发肿瘤进行了外显子组、低深度基因组和RNA测序分析,发现诊断时均存在体细胞BRCA1/2破坏,其中2例进展时通过拷贝数增加或剩余功能等位基因上调恢复BRCA功能,第3例持续应答超过7年且诊断时双等位体细胞缺失和功能丧失突变,无功能等位基因可供恢复,提示潜在治愈。

要点

  • 诊断时3例均存在体细胞BRCA1/2破坏。
  • 2例进展时通过拷贝数增加和/或剩余功能等位基因上调恢复BRCA。
  • 第3例持续应答超过7年,诊断时双等位体细胞缺失和功能丧失突变。

核心结论

  • 奥拉帕利对胚系BRCA1/2携带者之外的卵巢癌患者具有持久获益。
  • 癌细胞中BRCA1/2双等位缺失可能是对聚腺苷二磷酸核糖聚合酶抑制剂长期应答的潜在标志物,而同源修复功能恢复可能是疾病耐药的机制。

研究设计与样本

  • 对3例无胚系BRCA1/2突变、接受奥拉帕利单药治疗超过5年且疗效卓越的铂敏感复发性高级别浆液性卵巢癌患者的诊断和复发肿瘤进行外显子组、低深度基因组和RNA测序分析。

主要发现

  • 3例患者诊断时均观察到体细胞BRCA1/2破坏。
  • 2例患者进展时通过拷贝数增加和/或剩余功能等位基因上调恢复BRCA功能。
  • 第3例患者持续应答超过7年,诊断时肿瘤具有双等位体细胞缺失和功能丧失突变,缺乏可供恢复BRCA1活性的功能等位基因,提示潜在治愈。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Durable and long-term responses to the poly (ADP-ribose) polymerase inhibitor olaparib are observed in patients without BRCA1/2 mutations. However, beyond BRCA1/2 mutations, there are no approved biomarkers for olaparib in high-grade serous ovarian cancer (HGSOC). To determine mechanisms of durable response and resistance to olaparib therapy, we performed an analysis of HGSOC tumors from three patients without germline BRCA1/2 mutations who experienced exceptional responses to olaparib. Patients and Methods We performed integrated exome, low-pass genome, and RNA sequence analysis of tumors at diagnosis and upon relapse from patients with platinum-sensitive HGSOC recurrence who were treated > 5 years with olaparib therapy as a single agent. Results We observed somatic disruption of BRCA1/2 in all three patients at diagnosis, followed by subsequent BRCA recovery upon progression by copy number gain and/or upregulation of the remaining functional allele in two patients. The third patient with ongoing response (> 7 years) had a tumor at diagnosis with biallelic somatic deletion and loss-of-function mutation, thereby lacking a functional allele for recovery of BRCA1 activity and indicating a potential cure. Conclusion Olaparib has durable benefit for patients with ovarian cancer beyond germline BRCA1/2 carriers. These data suggest that biallelic loss of BRCA1/2 in cancer cells may be a potential marker of long-term response to poly (ADP-ribose) polymerase inhibition and that restoration of homologous repair function may be a mechanism of disease resistance.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017. PMID: 28221868. doi:10.1200/JCO.2016.71.3677

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。